Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953201 | 1.00 | LMNA (0.48) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL4667124 | 0.75 | CYP2C9 (0.48) | LMNACYP2C9SLC6A2SLC6A3CYP1A2 | |
| SCHEMBL3438658 | 0.74 | — | — | |
| SCHEMBL9387173 | 0.70 | LMNA (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL4722010 | 0.70 | CYP2C9 (0.55) | LMNACYP2C9SLC6A2SLC6A3CYP1A2 | |
| SCHEMBL2131516 | 0.70 | LMNA (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL2131520 | 0.70 | LMNA (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL2442821 | 0.70 | LMNA (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL24473924 | 0.70 | LMNA (0.38) | LMNACYP2C9TDP1 | |
| SCHEMBL15372499 | 0.70 | LMNA (0.38) | LMNACYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| EP-0498331-B1 | N-(aryloxyalkyl)heteroaryl-8-azabicyclo(3.2.1)octanes, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5340936-A | Antipsychotic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5334599-A | Heteroaryl-8-azabicyclo[3,2,1]octanes as antipsychotic agents, 5-HT3 receptor antagonists and inhibitors of the reuptake of serotonin | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0498331-A1 | N-(aryloxyalkyl)heteroaryl-8-azabicyclo(3.2.1)octanes, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | DPP4, DPP8, DPP7 | LMNA 3439/4885CYP2C9 2088/4885SLC6A2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.